AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha • Tuesday
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptSeeking Alpha • 11/13/26
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage ResultsMarketBeat • 11/12/26
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/26
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026Business Wire • 11/05/26
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingBusiness Wire • 10/08/26
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026Business Wire • 09/16/26
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026Business Wire • 09/02/26
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded WarrantsBusiness Wire • 08/13/26
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 08/11/26
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes TranscriptSeeking Alpha • 08/10/26